Poland Infection Control Market - Forecasts from 2020 to 2025
Poland infection control market is estimated to be valued at US$95.937 million in 2019 and is projected to grow steadily during the forecast period. Owing to the great scope of improvement of the polish healthcare sector, the Polish population has one of the lowest life expectancies in Europe. The Social Health Insurance system provides access to a broad scope of benefits but there are important coverage gaps, most notably for outpatient medicines. The health system tends to rely excessively on hospital care and faces shortages of health workers, particularly primary care doctors. The main causes of death are Ischaemic heart disease, followed by stroke and lung cancer. Moreover, above half the population have reported depression compared to a fifth in the European Union (EU). Despite the reduction of the rate of smoking the behavioral risk factors that account for almost half of all deaths in Poland. Binge drinking is rising among teenagers. The obesity rate is also above the EU average, particularly that observed among children that have doubled since 2001.
In 2017, compared to an average of 9.8% of GDP on health expenditure across the EU, Poland spent 6.5% of its GDP on health. Almost 70% of this spending came from public sources, a lower share than the average for EU (79%), 2016. The rest is predominantly paid out of pocket by households, primarily for outpatient medicines. Per person, health expenditure amounted to EUR 1507 (adjusted for differences in purchasing power), Out-of-pocket (OOP) spending accounted for 23% of all health spending, with the bulk of it spent on outpatient medicines. On the other hand, around two-thirds of adults aged 65 and over report having at least one chronic disease, with half of them reported having two or more. These health problems can result in functional disabilities: almost one-quarter of the Polish population aged 65 and over reports experiencing some limitations in basic activities of daily living (such as bathing, dressing or getting out of bed), which is around 5% points higher than the EU average. Besides, in 2017, over one third (34%) of health expenditure was spent on inpatient care amounting to 518 EUR PPP per capita and 488 EUR PPP per capita was spent on outpatient care. Further, the number of hospital beds per citizen has remained stable over the last decade.
However, a new regulation introduced in 2019, which ties employment quotas for hospital nurses with the number of hospital beds, is leading hospital management to reduce the number of beds in response to recent increases in nurses’ salaries. Despite the latter can retard the progress of healthcare expenditure marginally, the need for healthcare services to be provided is great especially on the account of chronic diseases repaired by the adult population aged 65 or over. Along with the aforementioned, the treatment of chronic disease needs longer inpatient care, among others. Thus, to avoid healthcare-associated illness the administration of various healthcare points needs to invest in a variety of infection control products which in turn is poised to drive the growth of Infection Control Market of Poland during the forecast period.
Segmentation
In 2017, compared to an average of 9.8% of GDP on health expenditure across the EU, Poland spent 6.5% of its GDP on health. Almost 70% of this spending came from public sources, a lower share than the average for EU (79%), 2016. The rest is predominantly paid out of pocket by households, primarily for outpatient medicines. Per person, health expenditure amounted to EUR 1507 (adjusted for differences in purchasing power), Out-of-pocket (OOP) spending accounted for 23% of all health spending, with the bulk of it spent on outpatient medicines. On the other hand, around two-thirds of adults aged 65 and over report having at least one chronic disease, with half of them reported having two or more. These health problems can result in functional disabilities: almost one-quarter of the Polish population aged 65 and over reports experiencing some limitations in basic activities of daily living (such as bathing, dressing or getting out of bed), which is around 5% points higher than the EU average. Besides, in 2017, over one third (34%) of health expenditure was spent on inpatient care amounting to 518 EUR PPP per capita and 488 EUR PPP per capita was spent on outpatient care. Further, the number of hospital beds per citizen has remained stable over the last decade.
However, a new regulation introduced in 2019, which ties employment quotas for hospital nurses with the number of hospital beds, is leading hospital management to reduce the number of beds in response to recent increases in nurses’ salaries. Despite the latter can retard the progress of healthcare expenditure marginally, the need for healthcare services to be provided is great especially on the account of chronic diseases repaired by the adult population aged 65 or over. Along with the aforementioned, the treatment of chronic disease needs longer inpatient care, among others. Thus, to avoid healthcare-associated illness the administration of various healthcare points needs to invest in a variety of infection control products which in turn is poised to drive the growth of Infection Control Market of Poland during the forecast period.
Segmentation
- By Product
- Disinfectants
- Sterilization
- Low-Temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. POLAND INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. POLAND INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. DE LAMA S.P.A.
8.2. H.W.Andersen Products Ltd.
8.3. Sartorius AG
8.4. SMS sp. z o.o.
8.5. Steriflow
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. POLAND INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. POLAND INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. DE LAMA S.P.A.
8.2. H.W.Andersen Products Ltd.
8.3. Sartorius AG
8.4. SMS sp. z o.o.
8.5. Steriflow
8.6. List is not Exhaustive*
